Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon May 26, 2024 9:08am
90 Views
Post# 36057826

RE:RE:RE:RE:ONCY presents 2 posters at ASCO 2024

RE:RE:RE:RE:ONCY presents 2 posters at ASCO 2024May 24, 2024 - Regeneron Pharmaceuticals released underwhelming bispecific Phase I/II data on its ongoing bispecific antibody study in patients with advanced solid tumors REGN7075 is a costimulatory bispecific antibody that is intended to work by bridging CD28-positive T cells with tumor cells expressing the EGFR protein. This mechanism of action was thought to allow REGN7075 to restore the immune sensitivity of tumor cells and activate the anti-cancer functions of T-cells. The effect was underwhelming.

The resulting overall response rate was 20%.


https://www.biospace.com/article/asco24-regeneron-s-bispecific-antibody-falls-flat-in-early-study-with-just-one-complete-response/
<< Previous
Bullboard Posts
Next >>